SGLT2 억제제와 만성콩팥병
SGLT2 Inhibition for Diabetic and Non-diabetic Kidney Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chronic kidney disease (CKD) can be progressive, and its prognosis is worse because of increased mortality when it is associated with diabetes and cardiac disease. The outcomes of diabetic kidney disease (DKD) need to be improved, despite multifactorial interventions including glucose and blood pressure (BP) control, and the use of renin-angiotensin system (RAS) inhibitors, statins, and aspirin. Recent clinical trials suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors offer additional cardiorenal protection in DKD and non-diabetic CKD on top of RAS inhibition. The action of SGLT2 inhibitors is derived from the proximal tubule of the kidney, but their systemic effects beyond glucose-lowering involve hemodynamic and non-hemodynamic mechanisms. First, SGLT2 inhibitors restore tubuloglomerular feedback and relieve glomerular hypertension and albuminuria. Second, natriuresis and renal glycosuria lead to fluid and weight loss, resulting in BP lowering and prevention of heart failure. Third, SGLT2 inhibitors have anti-inflammatory and anti-oxidative actions that can reduce renal and cardiac inflammation and fibrosis, probably via adenosine monophosphate-activated protein kinase and sirtuin-1 activation. Finally, the proximal tubular workload is relieved, accompanied by increased erythropoiesis. Hypoxia-inducible factor 1 may be stimulated by renal outer medullary hypoxia when tubular sodium transport shifts from the proximal convoluted tubule to the proximal straight tubule and thick ascending limb, due to SGLT2 inhibition. These effects may also be beneficial in non-diabetic CKD, and we anticipate that SGLT2 inhibitors will prove effective for albuminuria reduction and preservation of kidney function in primary kidney diseases, including glomerulonephritis.
Abstract
Chronic kidney disease (CKD) can be progressive, and its prognosis is worse because of increased mortality when it is associated with diabetes and cardiac disease. The outcomes of diabetic kidney disease (DKD) need to be improved, despite multifactorial interventions including glucose and blood pressure (BP) control, and the use of renin-angiotensin system (RAS) inhibitors, statins, and aspirin. Recent clinical trials suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors offer additional cardiorenal protection in DKD and non-diabetic CKD on top of RAS inhibition. The action of SGLT2 inhibitors is derived from the proximal tubule of the kidney, but their systemic effects beyond glucose-lowering involve hemodynamic and non-hemodynamic mechanisms. First, SGLT2 inhibitors restore tubuloglomerular feedback and relieve glomerular hypertension and albuminuria. Second, natriuresis and renal glycosuria lead to fluid and weight loss, resulting in BP lowering and prevention of heart failure. Third, SGLT2 inhibitors have anti-inflammatory and anti-oxidative actions that can reduce renal and cardiac inflammation and fibrosis, probably via adenosine monophosphate-activated protein kinase and sirtuin-1 activation. Finally, the proximal tubular workload is relieved, accompanied by increased erythropoiesis. Hypoxia-inducible factor 1 may be stimulated by renal outer medullary hypoxia when tubular sodium transport shifts from the proximal convoluted tubule to the proximal straight tubule and thick ascending limb, due to SGLT2 inhibition. These effects may also be beneficial in non-diabetic CKD, and we anticipate that SGLT2 inhibitors will prove effective for albuminuria reduction and preservation of kidney function in primary kidney diseases, including glomerulonephritis.
참고문헌 (37)
- Mather A, "Glucose handling by the kidney", Kidney Int Suppl, 120, pp.S1~S6 (2011)
- Landau BR, "Contributions of gluconeogenesis to glucose production in the fasted state", J Clin Invest, 98, pp.378~385 (1996)
- Stumvoll M, "Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity", Am J Physiol., 274, pp.E817~E826 (1998)
- Woerle HJ, "Pathways for glucose disposal after meal ingestion in humans", Am J Physiol Endocrinol Metab., 284, pp.E716~E725 (2003)
- Wright EM, "Biology of human sodium glucose transporters", Physiol Rev, 91, pp.733~794 (2011)
- Meyer C, "Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus", J Clin Invest, 102, pp.619~624 (1998)
- Meyer C, "Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes", Am J Physiol Endocrinol Metab., 287, pp.E1049~E1056 (2004)
- Rahmoune H, "Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes", Diabetes, 54, pp.3427~3434 (2005)
- Wilding JP, "The role of the kidneys in glucose homeostasis in type 2 diabetes : clinical implications and therapeutic significance through sodium glucose co-transporter 2inhibitors", Metabolism, 63, pp.1228~1237 (2014)
- Osswald H, "Adenosine mediates tubuloglomerular feedback response: an element of metabolic control of kidney function", Kidney Int Suppl., 32, pp.S128~S131 (1991)
- Tonneijck L, "Glomerular hyperfiltration in diabetes : mechanisms, clinical significance, and treatment", J Am Soc Nephrol, 28, pp.1023~1039 (2017)
- Cherney DZ, "Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus", Circulation, 129, pp.587~597 (2014)
- Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
- Wanner C, "Empagliflozin and progression of kidney disease in type 2 diabetes", N Engl J Med, 375, pp.323~334 (2016)
- Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
- Perkovic V, "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy", N Engl J Med, 380, pp.2295~2306 (2019)
- Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
- Heerspink HJL, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
- Wheeler DC, "Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease : a prespecified analysis from the DAPA-CKD trial", Lancet Diabetes Endocrinol, 9, pp.22~31 (2021)
- Wheeler DC, "A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy", Kidney Int, 100, pp.215~224 (2021)
- Cherney DZI, "Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease(DIAMOND) : a randomised, double-blind, crossover trial", Lancet Diabetes Endocrinol, 8, pp.582~593 (2020)
- McMurray JJV, "Dapagliflozin in patients with heart failure and reduced ejection fraction", N Engl J Med, 381, pp.1995~2008 (2019)
- Packer M, "Cardiovascular and renal outcomes with empagliflozin in heart failure", N Engl J Med, 383, pp.1413~1424 (2020)
- Anker SD, "Empagliflozin in heart failure with a preserved ejection fraction", N Engl J Med, 385, pp.1451~1461 (2021)
- Rhee JJ, "Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY", Diabetes Obes Metab, 22(Suppl 1), pp.46~54 (2020)
- Alicic RZ, "SGLT2 inhibition for the prevention and treatment of diabetic kidney disease : a review", Am J Kidney Dis, 72, pp.267~277 (2018)
- Verma S, "Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?", JACC Basic Transl Sci, 5, pp.180~182 (2020)
- Bruzzi I, "Role of increased glomerular protein traffic in the progression of renal failure", Kidney Int Suppl., 62, pp.S29~S31 (1997)
- Pessoa TD, "Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+", H+ exchanger isoform 3 activity in the renal proximal tubule, 2014, pp.25, 2028~2039
- Tuttle KR, "SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes : report of a scientific workshop sponsored by the National Kidney Foundation", Am J Kidney Dis, 77, pp.94~109 (2021)
- Kim S, "Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats", Hypertens Res, 42, pp.1905~1915 (2019)
- Zannad F, "Cardiorenal syndrome revisited", Circulation, 138, pp.929~944 (2018)
- Packer M, "SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry : a paradigm shift in understanding their mechanism of action", Diabetes Care, 43, pp.508~511 (2020)
- Heerspink HJL, "Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice(CVD-REAL 3) : a multinational observational cohort study", Lancet Diabetes Endocrinol, 8, pp.27~35 (2020)
- Kidney Disease: Improving Global Outcomes (KDIGO)Diabetes Work Group, "KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease", Kidney Int., 98, pp.S1~S115 (2020)
- Garofalo C, "SGLT2 inhibitors : nephroprotective efficacy and side effects", Medicina(Kaunas), 55, pp.268~ (2019)
- Chung S, "Use of anti-diabetic agents in non-diabetic kidney disease : from bench to bedside", Life(Basel), 11, pp.389~ (2021)